Website profile

Pharmadispatch

News of the Day Anticipated therapies and not-so-anticipated dominate July PBAC agenda GSK brings Melbourne discovered treatment 'home' to Australian patients New government report reveals the emerging impact of generational reform Health department quietly launches major review of blood products supply Budget reveals

  • 39articles · 30d
  • 14+ hour agolatest article
  • Aug 17, 2026earliest in window
  • 92%with images
  • 132avg words
articles per day
Categories
  • Medical 34
  • Health & Wellness 29
  • Health 27
  • Business & Industrial 10
  • Economy, Business & Finance 5
  • Finance & Business 4
  • Science & Technology 4
  • Human Interest 1

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News


pharmadispatch.com > news > scandal-hit-kpmg-still-holds-37-million-in-health-department-work

Scandal-hit KPMG still holds $37 million in health department work

1+ day, 2+ hour ago   (104+ words) PharmaDispatch Scandal-hit KPMG still holds $37 million in health department work According to the document released in response to a Freedom of Information request, the firm held 24 active contracts with the department, worth a combined $37.3 million as at 22 May 2026. … Todd Stephenson…...


pharmadispatch.com > news > canberra-details-tax-changes-with-limited-concessions-for-some-innovators

Canberra details tax changes with limited concessions for some innovators

1+ day, 4+ hour ago   (100+ words) PharmaDispatch Canberra details tax changes with limited concessions for some innovators AusBiotech has welcomed concessions to changes to the R&D Tax Incentive and Capital Gains Tax but remains concerned about the potential impact on emerging life sciences companies. … Rare…...


pharmadispatch.com > news > australia-secures-sovereign-viral-vector-manufacturing-as-vvmf-wins-tga-licence

Australia secures sovereign viral vector manufacturing as VVMF wins TGA licence

4+ day, 22+ hour ago   (159+ words) PharmaDispatch Australia secures sovereign viral vector manufacturing as VVMF wins TGA licence A Sydney company has become the first in Australia to earn a manufacturing licence for viral vectors, a milestone it says strengthens the nation's capacity to make advanced…...


pharmadispatch.com > news > melbourne-oncologist-takes-the-reins-at-australias-private-cancer-physicians-body

Melbourne oncologist takes the reins at Australia's private cancer physicians body

4+ day, 22+ hour ago   (154+ words) PharmaDispatch Melbourne oncologist takes the reins at Australia's private cancer physicians body After twelve years steering the Private Cancer Physicians of Australia through some of the most consequential fights in Australian cancer policy, Christopher Steer has handed the presidency to…...


pharmadispatch.com > news > five-years-1826-days-and-we-are-still-going-on-the-hta-review

Five years, 1,826 days, and we are still going on the HTA Review

1+ week, 22+ hour ago   (114+ words) PharmaDispatch Five years, 1,826 days, and we are still going on the HTA Review Today marks the fifth anniversary of former health minister Greg Hunt's announcement that Australia would conduct a review of health technology assessment. … The 'Dispatched' Week in Review…...


pharmadispatch.com > news > astellas-australia-turns-to-rare-disease-leader-guillaume-pfeiffer-for-next-chapter

Astellas Australia turns to rare disease leader Guillaume Pfeiffer for next chapter

2+ week, 22+ hour ago   (131+ words) PharmaDispatch Astellas Australia turns to rare disease leader Guillaume Pfeiffer for next chapter Astellas Australia has appointed Guillaume Pfeiffer as its new general manager, bringing more than two decades of experience across specialty medicines, rare diseases, oncology and advanced therapies…...


pharmadispatch.com > news > sandoz-earns-top-workplace-recognition-amid-push-for-medicine-access

Sandoz earns workplace recognition amid push for medicine access

2+ week, 3+ day ago   (132+ words) PharmaDispatch Sandoz earns workplace recognition amid push for medicine access Sandoz Australia and New Zealand has been named among Australia’s Top 100 Best Workplaces for 2026, ranking 15th in the medium-sized business category and standing as the only pharmaceutical company included in that…...


pharmadispatch.com > news > insurers-warn-cut-could-hit-australians-most-likely-to-need-cancer-care

Insurers warn cut could hit Australians most likely to need cancer care

2+ week, 6+ day ago   (124+ words) PharmaDispatch Insurers warn cut could hit Australians most likely to need cancer care The organisation has pointed to the potential impact on cancer treatment and care, highlighting that the policyholders impacted by the reduction are more likely than any other…...


pharmadispatch.com > news > new-zealand-researchers-honoured-for-work-tackling-superbugs-and-blood-cancer

New Zealand researchers honoured for work tackling superbugs and blood cancer

3+ week, 4+ day ago   (138+ words) PharmaDispatch New Zealand researchers honoured for work tackling superbugs and blood cancer Two New Zealand scientists working at very different points of the medicines-development pipeline will be recognised tonight at Medicines New Zealand’s 2026 Value of Medicines Awards. … Opportunity #1 - biosimilar policy…...


pharmadispatch.com > news > wesfarmers-health-evolves-its-loyalty-program-with-new-pulse-rewards

Wesfarmers Health evolves its loyalty program with new Pulse Rewards

3+ week, 6+ day ago   (140+ words) PharmaDispatch Wesfarmers Health evolves its loyalty program with new Pulse Rewards Wesfarmers Health has launched Pulse Rewards, bringing its pharmacy, health, and beauty brands together under a single loyalty platform that rewards customers across a broader range of everyday health…...